Organovo Holdings Recieves Award From Popular Science

Organovo Holdings’ (NYSE MKT:ONVO) 3D bioprinted kidney tissue has received a “Best of What’s New” Award from Popular Science magazine, identifying it as one of 2015’s 100 greatest innovations.
According to the press release:

“Organovo is proud to be named a top health innovator for this year by Popular Science, a leading science and technology magazine,” said Keith Murphy, chairman and chief executive officer of Organovo.  “The past year has been important for us as we successfully launched our exVive3D^TM Human Liver Tissue and continue to grow the market for bioprinted tissues in drug research and development.  We’re excited to advance our next portfolio offering of 3D human kidney tissue.”
“The Best of What’s New awards honor the innovations that surprise and amaze us—those that challenge our view of what’s possible in the future,” said Cliff Ransom, Editor-in-Chief of Popular Science.  “The award is Popular Science’s top prize, and the 100 winners—chosen from among thousands of nominees—are each a revolution in their respective fields.”
Organovo’s 3D bioprinting enables the reproducible, automated creation of living human tissues that mimic the form and function of native tissues in the body.  The Company is building a number of 3D tissue models for research and drug discovery applications, as well as working to fulfill their vision of building human tissues for surgical therapy and transplantation.  Organovo is also on track to bring its 3D bioprinted human kidney tissue to the broader commercial market in 2016 for use in toxicology and other preclinical drug testing.
The Company has announced collaborations with L’Oreal to develop 3D printed skin tissue for product evaluation and other areas of advanced research, with Merck to develop multiple custom tissue models for drug development, and with the Yale School of Medicine to develop 3D organ tissues for surgical transplantation research.

Click here to read the full press release.